|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2007-7-19
|
|
pubmed:abstractText |
The clinical literature suggests that atorvastatin therapy achieves a reduction in major cardiovascular events within the first year of therapy. Aside from obvious clinical benefits, economic advantage may also result from this observation. The present analysis modeled the clinical and economic consequences of initiating atorvastatin versus generic simvastatin in defined US managed care organization patient populations.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1473-4877
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1517-29
|
|
pubmed:meshHeading |
pubmed-meshheading:17535539-Angina, Unstable,
pubmed-meshheading:17535539-Anticholesteremic Agents,
pubmed-meshheading:17535539-Cardiovascular Diseases,
pubmed-meshheading:17535539-Coronary Disease,
pubmed-meshheading:17535539-Costs and Cost Analysis,
pubmed-meshheading:17535539-Diabetes Mellitus,
pubmed-meshheading:17535539-Drug Costs,
pubmed-meshheading:17535539-Female,
pubmed-meshheading:17535539-Heptanoic Acids,
pubmed-meshheading:17535539-Humans,
pubmed-meshheading:17535539-Male,
pubmed-meshheading:17535539-Models, Theoretical,
pubmed-meshheading:17535539-Pyrroles,
pubmed-meshheading:17535539-Simvastatin,
pubmed-meshheading:17535539-United States
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
|
|
pubmed:affiliation |
University of Minnesota, Minneapolis, MN, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
